Market revenue in 2021 | USD 9,244.4 million |
Market revenue in 2030 | USD 16,747.2 million |
Growth rate | 6.8% (CAGR from 2021 to 2030) |
Largest segment | Mammalian |
Fastest growing segment | Non-mammalian |
Historical data covered | 2017 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Mammalian, Non-mammalian |
Key market players worldwide | Boehringer Ingelheim, Lonza Group Ltd, Innovent Biologics Inc, Rentschler Biopharma SE, JRS Pharma, AGC Inc, Probiogen, FUJIFILM Holdings Corp, Toyobo Co Ltd, Samsung BioLogics, Thermo Fisher Scientific Inc, R1 RCM Inc, WuXi Biologics (Cayman) Inc, AbbVie Inc, Binex, Charles River Laboratories International Inc, Icon PLC, PAREXEL, Labcorp Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical cmo and cro market will help companies and investors design strategic landscapes.
Mammalian was the largest segment with a revenue share of 55.82% in 2021. Horizon Databook has segmented the Asia Pacific biopharmaceutical cmo and cro market based on mammalian, non-mammalian covering the revenue growth of each sub-segment from 2017 to 2030.
The Asia Pacific biopharmaceuticals CMO & CRO market is growing at a significant rate and the region is expected to emerge as the fastest-growing market for biopharmaceutical R&D and manufacturing. This growth can be attributed to various factors, such as regulatory changes, improving infrastructure, and presence of a large number of potential study subjects.
Several biopharma companies from the U.S. are considering development of pharma products in Asian countries owing to growing cost of R&D in their home country. Low-cost production facilities and cheap labor are available in Asian countries.
Moreover, conducting clinical trials in Asian countries, such as India, is relatively less expensive as compared to western countries, and this has also resulted in migration of several companies to this region.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific biopharmaceutical cmo and cro market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific biopharmaceutical cmo and cro market from 2017 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account